In agreement, several other studies reported similar findings regarding the predictive value of PIK3CA mutations for the benefits of adjuvant aspirin use in CRC patients, as concluded in two separate meta-analyses to synthesize these results [14,30]. Here, PIK3CA is linked to colorectal carcinoma.